Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa
Am J Clin Dermatol. 2025 Apr 12. doi: 10.1007/s40257-025-00942-y. Online ahead of print. ABSTRACT BACKGROUND: Patients with dystrophic epidermolysis bullosa have pathogenic variants in COL7A1, …